Andre Uddin of Research Capital maintained a “Speculative Buy” rating and C$14.00 price target o... Read More
In a Nov. 5 update, Research Capital analyst André Uddin reiterated his “Speculative Buy” ratin... Read More
Leede Financial has initiated coverage of Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Q... Read More
Research Capital analyst Andre Uddin reiterated a “Speculative Buy” rating and C$12.00 target pr... Read More
Research Capital analyst Andre Uddin maintained a “Speculative Buy” rating and C$12.00 target pr... Read More
Research Capital’s Andre Uddin said August 13 he remains focused on Eupraxia Pharmaceuticals’ (E... Read More
Following results that have sent the stock northward, Research Capital analyst Andre Uddin remains b... Read More
Following the announcement of a new financing, Raymond James analyst Rahul Sarugaser has lowered his... Read More
Following the release of new data, Raymond James analyst Rahul Sarugaser remains bullish about Eupra... Read More
Following new data from the company, Raymond James analyst Rahul Sarugaser has raised his price targ... Read More
More good news from Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Charts, News, An... Read More
The first half of 2023 has definitely been kinder to tech stocks, and investors have likely recouped... Read More
Raymond James analyst Rahul Sarugaser has been singing the praises of biotech company Eupraxia Pharm... Read More
Raymond James analyst Rahul Sarugaser updated clients on Thursday on biotech company Eupraxia Pharma... Read More
Shares of Eupraxia (Eupraxia Stock Quote, Charts, News, Analysts, Financials TSX:EPRX) have rallied ... Read More
After meeting with a key opinion leader in the rheumatology field, Raymond James analyst Rahul Sarug... Read More
After meeting with a key opinion leader in the gastroenterology field, Raymond James analyst Rahul S... Read More
Canadian biotech name Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Charts, News, ... Read More